Abstract
Background: Despite consensus guidelines, many men with low-grade prostate cancer are not managed with active surveillance. Patient perception of the nomenclature used to describe low-grade prostate cancers may partly explain this discrepancy. Methods: A randomized online survey was administered to men without a history of prostate cancer, presenting a hypothetical clinical scenario in which they are given a new diagnosis of low-grade prostate cancer. The authors determined whether diagnosis nomenclature was associated with management preference and diagnosis-related anxiety using ratings given on a scale from 1 to 100, adjusting for participant characteristics through multivariable linear regression. Results: The survey was completed by 718 men. Compared with Gleason 6 out of 10 prostate cancer, the term grade group 1 out of 5 prostate cancer was associated with lower preference for immediate treatment versus active surveillance (β = −9.3; 95% CI, −14.4, −4.2; P <.001), lower diagnosis-related anxiety (β = −8.3; 95% CI, −12.8, −3.8; P <.001), and lower perceived disease severity (β = −12.3; 95% CI, −16.5, −8.1; P <.001) at the time of initial diagnosis. Differences decreased as participants received more disease-specific education. Indolent lesion of epithelial origin, a suggested alternative term for indolent tumors, was not associated with differences in anxiety or preference for active surveillance. Conclusions: Within a hypothetical clinical scenario, nomenclature for low-grade prostate cancer affects initial perception of the disease and may alter subsequent decision making, including preference for active surveillance. Disease-specific education reduces the differential impact of nomenclature use, reaffirming the importance of comprehensive counseling and clear communication between the clinician and patient.
Original language | English (US) |
---|---|
Pages (from-to) | 3354-3360 |
Number of pages | 7 |
Journal | cancer |
Volume | 127 |
Issue number | 18 |
DOIs | |
State | Published - Sep 15 2021 |
Funding
This work was supported in part by the Specialized Programs of Research Excellence (SPORE) in Prostate Cancer (P50 CA180995 to Shilajit D. Kundu), National Institutes of Health grant 5U01CA196390 and Prostate Cancer Foundation grant SP0041136 (to Edward M. Schaeffer), and the 2019 Urology Care Foundation Residency Research Award Program and the Russell Scott, Jr, MD, Urology Research Fund (to Adam B. Weiner).
Keywords
- Gleason
- active surveillance
- nomenclature
- prostatic neoplasms
- survey study
ASJC Scopus subject areas
- Oncology
- Cancer Research